國立虎尾科技大學 |

Cancer Policy: Pharmaceutical Safety

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Cancer Policy: Pharmaceutical Safety/ edited by June M. McKoy, Dennis P. West.
其他作者:	McKoy, June M.
面頁冊數:	V, 128 p. 1 illus.online resource. :
Contained By:	Springer Nature eBook
標題:	Oncology . -
電子資源:	https://doi.org/10.1007/978-3-319-43896-2
ISBN:	9783319438962

Cancer Policy: Pharmaceutical Safety
Cancer Policy: Pharmaceutical Safety[electronic resource] /edited by June M. McKoy, Dennis P. West. - 1st ed. 2019. - V, 128 p. 1 illus.online resource. - Cancer Treatment and Research,1710927-3042 ;. - Cancer Treatment and Research,165.

Pharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.

Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.

ISBN: 9783319438962

Standard No.: 10.1007/978-3-319-43896-2doiSubjects--Topical Terms:

1253469
Oncology .

LC Class. No.: RC254-282

Dewey Class. No.: 616.994

Cancer Policy: Pharmaceutical Safety
LDR:03114nam a22003975i 4500 001 1010067
003 DE-He213
005 20200630065529.0
007 cr nn 008mamaa
008 210106s2019 gw | s |||| 0|eng d
020 $a 9783319438962 $9 978-3-319-43896-2
024 7 $a 10.1007/978-3-319-43896-2 $2 doi
035 $a 978-3-319-43896-2
050 4 $a RC254-282
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 616.994 $2 23
245 1 0 $a Cancer Policy: Pharmaceutical Safety $h [electronic resource] / $c edited by June M. McKoy, Dennis P. West.
250 $a 1st ed. 2019.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2019.
300 $a V, 128 p. 1 illus. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Cancer Treatment and Research, $x 0927-3042 ; $v 171
505 0 $a Pharmacovigilance programs: Do they improve Cancer Drug Safety? -- Impact of Cost on the Safety of Cancer pharmaceuticals -- Assessing pharmaceutical safety in Geriatric Oncology -- Cancer co-Morbidity: Implications for Drug Safety -- Statistical aids to signal generation: Are they effective in Identifying Adverse Cancer Drug Reactions? -- Pharmacovigilance of alternative medications in the Cancer Setting -- Key elements in Adverse Drug Interaction Safety Signals: evaluation of individual case reports in oncology -- Biosimilars: Are they really safe? -- Natural Language processing: improving the identification and communication of Cancer Drug Safety -- The Drug Shortage Crisis in the United States: Impact on cancer pharmaceutical safety -- Anatomy of Risk Evaluation and Mitigation Strategies (REMS) -- Cancer Drug Toxicity: Moving from patient to Survivor.
520 $a Cancer Policy: Pharmaceutical Safety provides invaluable information on the interesting and compelling field of cancer drug safety. Identifying and understanding high-priority policy issues and key pharmacovigilance strategies is of paramount importance. In this volume, outstanding and original chapters provide an overview and synthesis of the latest thoughts and findings relating to drug safety in the cancer domain. Topics include natural language processing and pharmacovigilance of alternative cancer pharmaceuticals. The information presented in this volume will improve understanding of emerging strategies to identify adverse drug reactions and drug-drug interactions within the cancer setting and will highlight policies that have been instituted to improve cancer patient safety. In summary, Cancer Policy: Pharmaceutical Safety explores many of the important areas of pharmacovigilance research in oncology.
650 0 $a Oncology . $3 1253469
650 0 $a Pharmacy. $3 582411
650 1 4 $a Oncology. $3 593951
650 2 4 $a Drug Safety and Pharmacovigilance. $3 1064651
700 1 $a McKoy, June M. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1304095
700 1 $a West, Dennis P. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1304096
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319438948
776 0 8 $i Printed edition: $z 9783319438955
830 0 $a Cancer Treatment and Research, $x 0927-3042 ; $v 165 $3 1254896
856 4 0 $u https://doi.org/10.1007/978-3-319-43896-2
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)